PARI Pharma's Nebulized DSCG Shows Results Similar to Inhaled Steroids in Asthma Studies Presen... (About PARI Pharma's novel 6% DSCG Formul...)

PARI Pharma's Nebulized DSCG Shows Results Similar to Inhaled Steroids in Asthma Studies Presented at ATS

Date:5/20/2009

About PARI Pharma's novel 6% DSCG Formulation

PARI's high concentrated isotonic DSCG formulation is an investigational proprietary aqueous solution of 6% DSCG with excipients already approved for inhalation. It is designed to be delivered via an optimized, small-droplet Investigational eFlow Nebulizer System or via PARI's paranasal drug delivery system, VibrENT. This provides the potential for the treatment of lower and upper respiratory diseases, such as asthma or sinusitis.

About the Investigational eFlow Nebulizer System and eFlow Technology

The Investigational eFlow Nebulizer System uses eFlow Technology to enable highly efficient aerosolization of liquid medications via a vibrating, perforated membrane that includes thousands of small holes that produce the aerosol mist. Compared to other nebulization technologies, eFlow Technology produces aerosols with a very high density of active drug, a precisely defined droplet size, and a high proportion of respirable droplets delivered in the shortest possible period of time. Combined with its silent mode of operation, small size (it fits in the palm of your hand), light weight, and battery use, products incorporating eFlow Technology reduce the burden of taking daily, inhaled treatments. The Investigational eFlow Nebulizer System and eFlow Technology are proprietary to PARI Pharma.

About PARI Pharma

PARI Pharma focuses on the development of aerosol delivery devices, drug formulations, and inhaled drug therapies. Based on PARI's 100-year history working with aerosols, PARI Pharma develops treatments for pulmonary and nasal administration optimized with advanced delivery technologies, such as eFlow Technology. PARI Pharma partners with pharmaceutical companies to develop new or improved therapies with eFlow Technology and other advanced delivery platforms. Investigational eFlow Nebulizer Systems are optimized and customized per investiga
'/>"/>

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. ePharmaSolutions Clinical Trial Investigator Portal Wins Bio-IT World 2009 Best Practice Award
2. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
3. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
4. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
5. Pharmasset Reports Fiscal Year End 2008 Financial Results
6. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
7. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
8. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
9. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
10. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
11. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)

Post Your Comments:

PARI Pharma's Nebulized DSCG Shows Results Similar to Inhaled Steroids in Asthma Studies Presen...(About PARI Pharma's novel 6% DSCG Formul...),Health